Affimed in the spotlight (part III)
A look at biotech market, NK cell sentiment, and AFMD update
Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the low-$80 range in the second half of the year. During this period, the industry saw advancements that improved fundamentals, including notable events such as:
Amgen’s $27B acquisition of Horizon Therapeutics
AstraZeneca & Daiichi’s Enhertu data for breast canc…